![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||
Copyright © 2007 Dove Medical Press Limited. All rights reserved PEGylation of nanoparticles improves their cytoplasmic transport 1Department of Biomedical Engineering; 2Department of Chemical and Biomolecular Engineering; 3The Institute for NanoBioTechnology, The Johns Hopkins University, Baltimore, MD, USA Correspondence: Justin Hanes, Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 N. Charles St., Baltimore, MD 21218, USA, Tel +1 410 516 3484, Fax +1 410 516 5510, Email hanes/at/jhu.edu Abstract The efficacy of nucleus-targeted drug- or gene-carrying nanoparticles may be limited by slow transport through the molecularly crowded cytoplasm following endosome escape. Cytoskeletal elements and cellular organelles may pose steric and/or adhesive obstacles to the efficient intracellular transport of nanoparticles. To potentially reduce adhesive interactions of colloids with intracellular components, the surface of model nanoparticles was coated with polyethylene glycol (PEG). Subsequently, multiple-particle tracking (MPT) was used to quantify the cytoplasmic transport rates of particles microinjected into the cytoplasm of live cells. PEGylation increased average nanoparticle diffusivities by 100% compared to unPEGylated particles (time scale of 10 s) in live cells. Faster particle transport correlated with a marked decrease in the number of particles that underwent hindered transport, from 79.2% (unmodified) to 48.8% (PEGylated). This result adds to an impressive list of positive benefits associated with PEGylation of drug and gene delivery vectors. Keywords: PEG, polystyrene, particle tracking, cytoplasm, microinjection Introduction Targeted intracellular delivery of drugs and genes to the cell nucleus involves the transport of delivery vehicles through the crowded cytoplasm (Lechardeur et al 2005; Pack et al 2005). In addition to steric hindrances, adhesive interactions with intracellular components may act to significantly reduce the cytoplasmic transport rates of therapeutic colloids. Nonviral polyethylenimine (PEI)/DNA nanocomplexes are actively transported along microtubules to the perinuclear region of cells within 30 minutes post-transfection (Suh et al 2003). However, vectors that successfully escape endosomes in the perinuclear region of cells may still have to traverse distances of up to several micrometers through the molecularly crowded cytoplasm prior to reaching nuclear pore complexes, the entryway into the nucleus. Therefore, inefficient transport of particles outside of endosomes may critically limit effective drug and gene therapies. Surface-modification of delivery vehicles with polyethylene glycol (PEG), or PEGylation, has shown promise as a method to improve the stability and in vivo performance of various non-viral drug and gene vectors (Sanders et al 2002; Ogris et al 2003; Lenter et al 2004; Mishra et al 2004; Pun et al 2004; Sun et al 2005; Zahr et al 2005). In addition, PEGylation has recently been shown to dramatically improve particle transport through biological obstacles, such as mucus from healthy volunteers (Lai et al 2007) or patients with cystic fibrosis (Hanes et al 2004). We hypothesized that PEGylation of therapeutic colloids may also improve their cytoplasmic transport (once the particles have escaped endosomal vesicles) by minimizing attractive forces to cytoskeletal elements, such as microtubules or actin filaments, or to other intracellular organelles. Here, multiple particle tracking (MPT) (Suh et al 2003, 2004, 2005) is used to compare the real time transport rates of individual PEGylated and unPEGylated polymeric nanoparticles in live cells. Materials and methods Cell culture HeLa cells (American Type Culture Collection, Manassas, VA) were cultured at 37 °C in 5% CO2 in minimum essential medium (MEM, Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen Corp., Carlsbad, CA) and 1% penicillin/streptomycin (Invitrogen Corp., Carlsbad, CA). Cells were grown on 35-mm glass-bottom dishes (MatTek Corp., Ashland, MA). Covalent PEGylation of nanoparticles Di-amine polyethylene glycol (PEG) of molecular weight 3,400 daltons (Nektar Therapeutics, San Carlos, CA) was dissolved in 50 mM 2-(N-morpholino)ethanesulfonic acid (MES, Sigma, St Louis, MO) buffer at pH 6.0. The use of di-amine PEG may result in a free amine group at the end of the surface-bound PEG chains. Yellow-green fluorescent polystyrene nanospheres (Molecular Probes, Eugene, OR) were added to the solution to give final concentrations of 10 mg PEG/ml and 1% solids/ml. The nanospheres had diameters of 100 nm and were carboxyl-modified. Following a 15 min incubation at room temperature, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDAC, Sigma, St Louis, MO) was added to the mixture to a concentration of 4 mg/ml. The pH of the solution was adjusted to 6.5 with dilute NaOH and incubated on an orbital shaker for 2 h at room temperature. To quench the reaction, glycine (JT Baker, Phillipsburg, NJ) was added to give a final concentration of 100 mM. The solution was incubated for 30 min at room temperature and subsequently dialyzed extensively against Dulbecco’s phosphate-buffered saline (PBS) in a 300,000 kDa MWCO Float-a-lyzer (Spectrum Laboratories, Rancho Dominguez, CA). Unmodified microspheres were dialyzed similarly to remove all traces of sodium azide originally added by the manufacturer. Microinjection of particles Prior to microinjection, solutions of PEGylated (PS-PEG) and unmodified nanospheres (PS) were diluted to approximately 1.8 × 107 particles/ml in distilled water, filtered through a 0.22 μm syringe filter (Millipore, Billerica, MA) and stored at 4 ºC. Nanospheres were injected using an Eppendorf Femto-Jet™ (Brinkmann Instruments, Westbury, NY) at a pressure of 180 hPa for 1.5s. Microinjection needles, Femtotips I (Brinkmann Instruments, Westbury, NY), were backloaded with 10 μl of particle solution using microloader pipetters (Brinkmann Instruments, Westbury, NY). Cells were microinjected at 37 °C in tissue culture medium supplemented with 150 mM HEPES (Sigma, St Louis, MO). To facilitate the location of microinjected cells for microscopy, cells were microinjected only in the vicinity of a cross-mark inscribed onto the dish with a diamond-tipped glass scribe. After microinjection, cells were immediately washed twice with PBS, supplied with fresh tissue culture medium, and incubated for 2 h before observation under fluorescence microscopy. Endocytosis of particles HeLa cells were incubated in the presence of approximately 1.8 × 1010 PS particles in 1 mL of cell culture media for 3 h at 37 °C. Prior to observation under fluorescence microscopy, cells were washed twice with PBS and new media added. Fluorescence microscopy and multiple particle tracking Cells were maintained at 37 °C with an air stream stage incubator (Nevtek, Burnsville, VA) and observed with an inverted epifluorescence microscope, Axiovert (Carl Zeiss Inc., Thornwood, NY), equipped with a 100X/1.4 NA oil-immersion lens. Movies of particle transport in live HeLa cells were obtained at 15 frames per second with a Princeton Pentamax camera (Roper Scientific, Trenton, NJ). The movies were analyzed with the Tracking Objects application in MetaMorph software (Universal Imaging Corp., Downing-town, PA) to obtain particle positions over time. This data was then used to calculate mean-square displacements (MSD) and effective diffusivities (Deff) of individual particles as shown previously (Suh et al 2003; Suh et al 2004). Briefly, MSD and Deff of individual particles in two dimensions are
Results and discussion Effect of PEGylation on cytoplasmic transport rates In this study, we quantitatively investigated whether the cytoplasmic transport of nanoparticles can be improved by surface modification with PEG. The covalent conjugation of PEG onto the surface of model drug delivery particles, 100 nm polystyrene (PS) nanoparticles, doubles their average transport rate in cells (at a time scale of 10s), as measured by ensemble-averaged mean-square displacement (Figure 1A
Average particle diffusivity values for both PS and PS-PEG decrease over time scale (Figure 1B To further characterize the differences in the intracellular transport of PS versus PS-PEG, the motions of individual nanoparticles were classified into three transport modes (Suh et al 2005): diffusive, active, and hindered (encompassing immobile and sub-diffusive particles). Classification of transport modes Kusumi and coworkers (Kusumi et al 1993) defined a stationary, or immobile, mode of transport that reflects the tight adhesion of the transporting species to rigid cellular components. The diffusivity of stationary proteins was obtained by assuming that the short-range motion of actively transporting species (in this case transmembrane proteins) is likely due to the small structural fluctuations of the cytoskeleton to which the proteins are attached. (To be actively transported, the proteins need to be closely associated with cytoskeletal filaments, such as actin, that underlie the plasma membrane.) Unfortunately, a similar methodology could not be applied to the particles in this study since microtubules in the cytoplasm of cells can experience substantial thermal fluctuation (data not shown). Particles tightly adhered to microtubules, therefore, may display diffusivity values on the order of particles moving by diffusive or sub-diffusive modes. Multi-color confocal particle tracking studies are underway to directly visualize the interaction of particles with fluorescently labeled microtubules in live cells. These studies should help directly determine the extent to which particles adhere to cytoskeletal structures as well as estimate their transport rates. Until then, we have assigned particles as immobile if their diffusivities are not above background noise in the particle tracking system. To determine the mode of transport (ie, diffusive, sub-diffusive, or active) of the mobile nanoparticles, a parameter called Relative Change (RC) is calculated for each particle. RC is defined as
Due to the random nature of diffusion, however, the RC values of a population of purely diffusive particles will have a certain spread around the value 1. Therefore, a Monte Carlo simulation of 10,000 random walks was used to predict this distribution of RC values. Similar to other work in the literature, the Monte Carlo simulated random walks are based on a continuum model with a fixed step size and unrestricted angle of jump (Saxton 1994). The angle θ, between 0 and 2π, is generated with uniform probability and the tracer particle is moved at each fixed time interval Δτ by
From this theoretical RC distribution of purely diffusive particles, upper and lower RC bounds are obtained by placing 95% of the values between the upper and lower bounds. Figure 2
Next, by calculating the RC values of each microinjected particle for the two time regimes (ie, short and long time scales), one can obtain the transport mode that describes the particle transport properties over the different length scales. For example, if the RCshort for a microinjected particle falls below the lower RC bound in Figure 2A
Effect of PEGylation on particle transport modes Based on the methodology from the previous section, the transport of microinjected nanoparticles was first categorized into immobile and mobile populations. Particles were classified as immobile if their diffusivities were indistinguishable from the noise in our experimental setup. The short-range and long-range transport of mobile particles was then further classified into three modes: diffusive, sub-diffusive, and active. Diffusive particles are undergoing unrestricted Brownian motion, sub-diffusive particles display hindered motion (possibly due to cytoplasmic obstacles, such as cytoskeletal structures), and actively transported particles likely experience motor protein-mediated transport along the cytoskeleton. Lastly, the immobile and sub-diffusive groups were combined into one hindered transport group. The majority of both PS and PS-PEG nanoparticles experience hindered transport at short time scales (Figures 3A
The overall mode of transport of PS and PS-PEG particles was then determined based on the transport mode assignments at the short and long time scales (Table 1). Almost 80% of microinjected PS particles experience hindered transport in the cytoplasm of live cells (Figure 4
Unexpectedly, about 13% of PS-PEG particles are classified as actively transported compared to 3% for unmodified PS. Based on the statistical criteria set forth in the previous section, only about 2.5% of purely diffusive particles should be classified as active in order to be within expected error. It is possible that the 13% of PS-PEG particles categorized as actively transported were endocytosed during the microinjection, resulting in particles within endosomes. Previous work has shown polymeric gene vectors within endosomes experience active transport (Suh et al 2003). Several factors, however, make the endocytosis of PS-PEG during microinjection highly unlikely. First, carboxylated PS particles (as used in this study) are not internalized readily by cells and require greater than one-hour incubation in the presence of a high particle concentration to observe particle endocytosis (data not shown). The duration of microinjection in our studies lasts less than 30 minutes and the cells are washed twice and replenished with new media directly after microinjection. In addition, attachment of PEG to the surfaces of particles has been observed to decrease particle endocytosis (Ogris et al 2001). When PS particles do enter cells via endocytosis (Figure 5
In conclusion, PEGylation of polymeric nanoparticles improves their cytoplasmic transport rates (outside of endosomal vesicles), possibly by reducing non-specific adhesion to cytoskeletal elements. This property may be important in allowing drug/gene vectors, which have escaped endosomes, to efficiently reach the nucleus. Acknowledgments The authors thank Daniel Naiman (Johns Hopkins University, Department of Mathematical Sciences) for his guidance in the classification of transport modes, and Yixian Zheng (Howard Hughes Medical Institute) for assistance with microinjection. This work was supported by the National Science Foundation (BES 9978160 and BES 0346716), the National Institutes of Health (T32-GM07057), a PGSD fellowship to S.K.L. from the National Science and Engineering Research Council of Canada, and an ARCS fellowship to J.S. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||
Adv Drug Deliv Rev. 2005 Apr 5; 57(5):755-67.
[Adv Drug Deliv Rev. 2005]Nat Rev Drug Discov. 2005 Jul; 4(7):581-93.
[Nat Rev Drug Discov. 2005]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):3878-82.
[Proc Natl Acad Sci U S A. 2003]Gene Ther. 2002 Mar; 9(6):363-71.
[Gene Ther. 2002]J Control Release. 2003 Aug 28; 91(1-2):173-81.
[J Control Release. 2003]Pharm Res. 2004 Apr; 21(4):683-91.
[Pharm Res. 2004]Eur J Cell Biol. 2004 Apr; 83(3):97-111.
[Eur J Cell Biol. 2004]Cancer Biol Ther. 2004 Jul; 3(7):641-50.
[Cancer Biol Ther. 2004]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):3878-82.
[Proc Natl Acad Sci U S A. 2003]Biotechnol Prog. 2004 Mar-Apr; 20(2):598-602.
[Biotechnol Prog. 2004]Adv Drug Deliv Rev. 2005 Jan 2; 57(1):63-78.
[Adv Drug Deliv Rev. 2005]Adv Drug Deliv Rev. 2005 Jan 2; 57(1):63-78.
[Adv Drug Deliv Rev. 2005]Biophys J. 1994 Feb; 66(2 Pt 1):394-401.
[Biophys J. 1994]Biophys J. 1996 Mar; 70(3):1250-62.
[Biophys J. 1996]Biophys J. 2002 Dec; 83(6):3162-76.
[Biophys J. 2002]J Cell Biochem. 1993 Jun; 52(2):140-7.
[J Cell Biochem. 1993]Adv Drug Deliv Rev. 2005 Jan 2; 57(1):63-78.
[Adv Drug Deliv Rev. 2005]Biophys J. 1993 Nov; 65(5):2021-40.
[Biophys J. 1993]J Biol Chem. 2003 Dec 12; 278(50):50393-401.
[J Biol Chem. 2003]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):3878-82.
[Proc Natl Acad Sci U S A. 2003]Biotechnol Prog. 2004 Mar-Apr; 20(2):598-602.
[Biotechnol Prog. 2004]Biomacromolecules. 2005 Sep-Oct; 6(5):2541-54.
[Biomacromolecules. 2005]Biophys J. 1994 Feb; 66(2 Pt 1):394-401.
[Biophys J. 1994]Biotechnol Prog. 2004 Mar-Apr; 20(2):598-602.
[Biotechnol Prog. 2004]Biophys J. 1994 Feb; 66(2 Pt 1):394-401.
[Biophys J. 1994]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):3878-82.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):3878-82.
[Proc Natl Acad Sci U S A. 2003]